Home > Dermatology > SPIN 2019 > Advances in Therapy > Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies

Brodalumab onset of action is significantly faster than ustekinumab: Results from the phase 3 AMAGINE-2 and -3 studies

Presented By
Dr Sandra Philipp, Charité-Universitätsmedizin Berlin, Germany
Conference
SPIN 2019
Trial
Phase 3, AMAGINE
Treating psoriasis patients with brodalumab achieves complete skin clearance more rapidly than ustekinumab. Although efficacy is obviously important, Dr Sandra Philipp (Charité-Universitätsmedizin Berlin, Germany) pointed out that patients rate the speed at which their disease improves as their most important treatment goal [1]. In the phase 3 AMAGINE-2 and AMAGINE-3 trials, Lebwohl et al. set out to describe and compare the onset of action, measured as the improvements in efficacy and quality of life, of brodalumab and ustekinumab in patients with moderate-to-severe psoriasis [2]. This pooled analysis included data from patients who were randomised to constant ustekinumab (n=590) or brodalumab (n=339) 210 mg every 2 weeks. Efficacy was measured at...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on